Goldman Sachs Leads $43M Funding for Website Platform NGINX

Programming, Software,

NGINX Inc., a Web application delivery platform company built on the open-source Web server NGINX, announced today it raised $43 million in a Series C fundraising to advance its system for helping clients modernize their websites.

The funding round, which brings NGINX’s total venture capital haul to $103 million, was led by Goldman Sachs Growth Equity, a venture capital and later-stage equity investment unit of financial firm Goldman Sachs. David Campbell, a managing director in Goldman Sachs’s merchant banking division, will become a NGINX board member.

The San Francisco-based company has assembled a suite of open source and commercial software tools to help website developers keep up with the demand for rapid improvements in speed and consumer experiences. NGINX promotes the conversion from traditional Web application architectures—which can become unwieldy and hard to change as they scale up—to a microservices application design, which splits website functions into simpler and separate elements that communicate with each other.

NGINX says it has more than 1,500 customers, including more than 30 percent of the Fortune 50 companies, and powers 450 million websites worldwide. The company’s investors include Blue Cloud Ventures, e.ventures, Index Ventures, MSD Capital, New Enterprise Associates, Runa Capital, and Telstra Ventures.

Photo credit:Vicente Barcelo Varona, Depositphotos.com

Author: Bernadette Tansey

Bernadette Tansey is a former editor of Xconomy San Francisco. She has covered information technology, biotechnology, business, law, environment, and government as a Bay area journalist. She has written about edtech, mobile apps, social media startups, and life sciences companies for Xconomy, and tracked the adoption of Web tools by small businesses for CNBC. She was a biotechnology reporter for the business section of the San Francisco Chronicle, where she also wrote about software developers and early commercial companies in nanotechnology and synthetic biology.